Business
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
Every two weeks remains approved as a dosing regimen of Elfabrio in the EUPARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its
About this update from Protalix Biotherapeutics, Inc. (de)
[{"type":"image","alt":"Chiesi Global Rare Diseases; Protalix Biotherapeutics","displaySize":"","headline":null,"caption":"Chiesi Global Rare Diseases; Protalix Biotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/9ef765237cc81158e8a73228d21a22b4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Y0m00zdCu20g_4gFOTuo2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9ef765237cc81158e8a73228d21a22b4","width":300,"height":138}},"lazy":false},{"type":"text","content":"Every two weeks remains approved as a dosing regimen of Elfabrio in the EU","length":74,"tagName":"p"},{"type":"text","content":"PARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, acknowledge that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the request to approve the dosing regimen of 2 mg/kg body weight infused every 4 weeks (E4W) for Elfabrio (pegunigalsidase alfa, in addition to the currently approved dosing regimen of 1 mg/kg body weight infused every 2 weeks (E2W).","length":883,"tagName":"p"},{"type":"text","content":"“We are disappointed by the result of this review but want to express our immense appreciation for the collaboration of the patient community, researchers and European Commission throughout this process,” said Giacomo Chiesi, Executive Vice President, Chiesi Global Rare Diseases. “We are proud to be a part of this community and will continue to prioritize the potential to advance and evolve safe and effective solutions for Fabry disease with reduced treatment burden.”","length":472,"tagName":"p"},{"type":"text","content":""We, together with Chiesi, remain committed to reducing the treatment burden for patients with Fabry disease," said Dror Bashan, Protalix's President and Chi...